Clearline Capital’s BridgeBio Pharma BBIO Stock Holding History

Clearline Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32,394	Closed	-$854K	–	105
2023 Q3	$854K	Sell	32,394 -230,526	-88%	-$6.54M	0.07%	106
2023 Q2	$4.52M	Sell	262,920 -2,120	-0.8%	-$31.9K	0.26%	52
2023 Q1	$4.39M	Sell	265,040 -27,200	-9%	-$317K	0.66%	45
2022 Q4	$2.23M	Buy	292,240 +11,338	+4%	+$109K	0.4%	62
2022 Q3	$2.79M	Sell	280,902 -149,674	-35%	-$1.56M	0.33%	64
2022 Q2	$3.91M	Buy	430,576 +74,512	+21%	+$623K	0.51%	50
2022 Q1	$3.61M	Buy	+356,064	New	+$3.65M	0.42%	56

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital's BBIO Position: Q4 2023 in Review

Clearline Capital sold out of BridgeBio Pharma (BBIO) in Q4 2023, closing a stake of 32,394 shares — an estimated $854K sold.

Clearline Capital first reported a position in BBIO in Q1 2022 and held it in 7 quarters. The position peaked at $4.52M in Q2 2023. 247 funds tracked by Wall St. Rank hold BBIO as of Q4 2023.

Clearline Capital reported no remaining BridgeBio Pharma position as of Q4 2023 after selling out during the quarter.
Clearline Capital sold 32,394 BridgeBio Pharma shares in Q4 2023, an estimated $854K.
Clearline Capital first reported a position in BridgeBio Pharma in Q1 2022 and held it in 7 quarters.
Clearline Capital's BridgeBio Pharma position peaked at $4.52M in Q2 2023.
247 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2023.

Based on Clearline Capital's 13F filing for Q4 2023, filed 14 Feb 2024.